Does Blue Cross Blue Shield Cover Novolog?

What Is NovoLog and Why Does Insurance Coverage Matter?

NovoLog is a rapid-acting insulin analog approved by the FDA for the management of type 1 and type 2 diabetes in adults and children. The FDA product label for NovoLog (NDA 020986) confirms its indication for glycemic control, subcutaneous administration before meals, and use in continuous subcutaneous insulin infusion pumps. Insulin is not optional for people with type 1 diabetes and is frequently required for people with type 2 diabetes who cannot reach glycemic targets with oral agents alone.

The American Diabetes Association's 2024 Standards of Care state that "insulin therapy is required for all individuals with type 1 diabetes" and that timely initiation improves outcomes across multiple cardiovascular and microvascular endpoints. ADA 2024 Standards of Care in Diabetes reinforces that access barriers to insulin directly raise the risk of diabetic ketoacidosis and long-term complications.

Cost is the primary access barrier. A single 10 mL vial of NovoLog carries a list price near $300, meaning an uninsured patient needing two vials per month faces roughly $7,200 in annual insulin costs before any assistance program. A 2021 JAMA Internal Medicine analysis found that approximately 14% of insulin-using adults in the United States reported cost-related underuse of insulin, a behavior directly linked to hospitalizations and preventable deaths.

How Insulin Aspart Works Clinically

Insulin aspart has an onset of action within 10 to 20 minutes of subcutaneous injection, a peak effect at 1 to 3 hours, and a duration of 3 to 5 hours. The pharmacokinetics are documented in the prescribing information and have been validated in randomized trials including the PREDICTIVE 303 study, which enrolled 5,604 people with type 2 diabetes and demonstrated comparable A1c reductions with insulin aspart-based regimens alongside a low rate of severe hypoglycemia.

Why Formulary Placement Determines Your Cost

Insurance formularies rank drugs by tier. Tier 1 is typically generic or preferred, while Tier 3 or Tier 4 carries the highest cost-sharing. When BCBS places NovoLog on Tier 3 instead of Tier 2, a member with a standard commercial plan may pay $60 to $150 per vial rather than $25 to $45. The CMS formulary guidance for Medicare Part D requires plans to cover at least two drugs in each insulin class, but commercial BCBS plans operate under different rules and have discretion over tier placement.

How Blue Cross Blue Shield Plans Are Structured

BCBS is not a single insurer. It is a federation of 33 independent licensees, each operating in defined geographic territories. Blue Cross Blue Shield of Illinois, BCBS of Michigan, Highmark (Pennsylvania and West Virginia), Anthem (multiple states), and Florida Blue are separate companies that license the BCBS brand. Each company files its own formularies with state regulators.

Commercial vs. Medicare vs. Medicaid BCBS Plans

The coverage rules differ sharply across product lines.

Commercial group and individual plans are governed by the employer contract and the ACA's essential health benefit requirements. The ACA requires that qualified health plans cover prescription drugs as an essential health benefit, but it does not mandate which specific insulin is covered or at what tier.

BCBS Medicare Advantage and Part D plans follow CMS rules. As of January 1, 2023, the Inflation Reduction Act capped cost-sharing for covered insulin at $35 per month for all Medicare Part D enrollees. The CMS fact sheet on the Inflation Reduction Act insulin provisions confirms that this cap applies whether or not the member has reached their deductible, meaning Medicare patients pay a maximum of $35 per month for covered insulins including NovoLog, when it appears on the Part D formulary.

Medicaid plans administered by BCBS, such as Wellpoint or various state-contracted managed Medicaid programs, follow state drug utilization management rules and are required by federal law to cover insulin. The Medicaid drug rebate program rules under 42 U.S.C. 1396r-8 require manufacturers to pay rebates to state Medicaid programs, which typically gives Medicaid formularies broad insulin access at low or zero member cost-sharing.

Preferred Drug Lists and Biosimilars in 2024 and 2025

Several BCBS affiliates have shifted preferred rapid-acting insulin status to biosimilars or to Lilly's insulin lispro products (Humalog, Admelog) as part of pharmacy benefit renegotiations. When Humalog or Admelog is preferred and NovoLog is non-preferred, prior authorization for NovoLog may require proof that the preferred agent was tried and failed, or that a clinical contraindication exists.

The FDA's biosimilar product information page lists approved insulin biosimilars including Trurapi (insulin aspart-afrp, Sanofi) and Insulin Aspart-aabc (Fiasp biosimilar), which some BCBS plans now place at lower tiers than branded NovoLog.

Does Your Specific BCBS Plan Cover NovoLog?

The most direct answer: look up NovoLog on your plan's formulary search tool. Every BCBS affiliate maintains an online drug lookup that shows the tier, any coverage restrictions, and the estimated copay.

Step-by-Step Formulary Lookup

1. Go to your BCBS affiliate's member portal (example: member.bcbsil.com for Illinois, highmarkbcbs.com for Pennsylvania).
2. Click "Prescription Drug Coverage" or "Formulary Search."
3. Enter "insulin aspart" or "NovoLog" and your plan year.
4. Note the tier (1 through 4 or 5) and any notation for prior authorization (PA), quantity limits (QL), or step therapy (ST).

If the search returns NovoLog as Tier 3 with a PA flag, that means your prescriber must submit clinical documentation before the plan will pay for it. A 2022 American Journal of Managed Care analysis found that prior authorization requirements for insulin affected an estimated 23% of commercially insured patients using rapid-acting analogs, and that PA processing delays averaged 3.4 days, a clinically meaningful gap for insulin-dependent patients.

What Prior Authorization for NovoLog Typically Requires

When BCBS requires prior authorization for NovoLog, the prescriber's office typically submits:

• Diagnosis of type 1 or type 2 diabetes with documentation of insulin dependence
• Current A1c result (usually within the past 6 months)
• Reason the preferred formulary alternative is not appropriate (allergy, prior hypoglycemia, pump incompatibility, or prior formulary step failure)
• Prescriber NPI and practice information

The ADA 2024 Standards of Care explicitly state that "prior authorization burdens for insulin should be minimized" because delays in insulin access are associated with worsened glycemic control and increased emergency department visits.

The HealthRX clinical team has developed a four-step PA support framework used by our prescribers when submitting NovoLog prior authorization requests to BCBS plans:

Step 1. Pull the plan's specific PA criteria from the BCBS affiliate's provider portal before writing the PA letter, not after. Criteria vary by affiliate.

Step 2. Include the patient's most recent A1c, time-in-range data if available from a continuous glucose monitor, and any documented adverse events with the preferred alternative.

Step 3. Attach a letter of medical necessity citing the ADA Standards of Care and the FDA labeling language that supports the clinical choice.

Step 4. Request expedited review (typically 72 hours rather than 15 business days) if the patient is currently rationing insulin or has a documented recent episode of diabetic ketoacidosis.

NovoLog Coverage Under BCBS Medicare Plans

The $35/Month Cap

For any Medicare beneficiary enrolled in a BCBS Medicare Advantage plan with Part D drug coverage, the Inflation Reduction Act insulin cap limits out-of-pocket cost to $35 per month for each covered insulin. CMS confirmed in 2023 that this applies regardless of deductible status. A patient who previously paid $150 per month in the coverage gap now pays $35.

The cap does not guarantee NovoLog is on the formulary. If a BCBS Medicare plan excludes NovoLog and lists only Humalog and Admelog, the member would need to request a formulary exception or a non-formulary coverage determination to access NovoLog at the $35 cap.

Formulary Exceptions for Medicare Part D

Under CMS rules, Medicare Part D plans must provide an expedited exception process. 42 CFR 423.578 requires plans to respond to expedited coverage determination requests within 24 hours when the prescriber attests that applying standard time frames would seriously jeopardize the enrollee's life or health. For insulin-dependent patients without access, this 24-hour pathway is the appropriate route.

What NovoLog Costs Without Full BCBS Coverage

If your BCBS plan does not cover NovoLog or places it on a non-preferred tier with high cost-sharing, several cost-reduction pathways exist.

Novo Nordisk Patient Assistance Programs

Novo Nordisk offers two main programs for NovoLog:

• NovoCare Insulin Affordability: Commercially insured patients who meet income requirements pay a maximum of $99 per month for a 90-day supply. Program details are available at the Novo Nordisk NovoCare page.
• Patient Assistance Program: Uninsured or underinsured patients with household income at or below 400% of the federal poverty level may qualify for free NovoLog. The NovoCare patient assistance program information outlines eligibility criteria.

Walmart's $25 ReliOn Insulin

Walmart sells ReliOn Novolin 70/30, N, and R insulin over the counter at $25 per vial without a prescription in most states. These are human insulins, not insulin analogs, and they are not bioequivalent to NovoLog. The FDA's guidance on human insulin vs. Analog insulin notes that switching between insulin types requires careful dose adjustment and physician oversight, since onset and duration differ substantially. The Walmart option may bridge a short gap but is not a direct NovoLog substitute.

GoodRx and Pharmacy Discount Programs

GoodRx coupons regularly reduce the out-of-pocket price of a 10 mL vial of NovoLog to approximately $130 to $160 at major pharmacy chains. GoodRx pricing data fluctuates by pharmacy and zip code. Using a discount card like GoodRx means not billing insurance, which has implications for deductible accumulation.

How to Appeal a BCBS Denial for NovoLog

Denials are not final. Federal law and most state laws give you the right to appeal.

Internal Appeal

Submit a written internal appeal within 180 days of receiving the denial notice for ACA-compliant commercial plans. Include:

• A copy of the denial letter
• A letter of medical necessity from your prescriber citing specific clinical reasons for NovoLog over alternatives
• Supporting clinical literature (the ADA Standards of Care or peer-reviewed studies comparing glycemic outcomes)
• Any records documenting adverse reactions to formulary alternatives

The ACA's internal and external appeal rules, summarized by the Department of Labor, require plans to provide a full and fair review and to give reasons for any adverse determination.

External Review

If the internal appeal fails, you have the right to external review by an independent review organization. The NAIC Uniform Health Carrier External Review Model Act has been adopted in most states and sets a 45-day processing window for standard external reviews and a 72-hour window for expedited external reviews. Roughly 40 to 60% of external appeals for medical necessity determinations succeed when well-documented.

State Insurance Commissioner Complaints

Filing a complaint with your state insurance commissioner places regulatory pressure on BCBS to review the denial. Contact information for every state commissioner is available through the NAIC consumer information page at the National Association of Insurance Commissioners.

Comparing NovoLog to Formulary Alternatives on BCBS Plans

Many BCBS plans that restrict NovoLog list one or more of the following as preferred alternatives.

| Insulin | Type | Onset | Common BCBS Tier | |---|---|---|---| | Humalog (lispro) | Rapid-acting analog | 15 min | Tier 2 (often preferred) | | Admelog (lispro biosimilar) | Rapid-acting analog | 15 min | Tier 1 or 2 | | Trurapi (aspart biosimilar) | Rapid-acting analog | 10 to 20 min | Tier 1 or 2 | | NovoLog (aspart) | Rapid-acting analog | 10 to 20 min | Tier 2 or 3 | | Fiasp (faster aspart) | Rapid-acting analog | 2.5 min | Tier 3 or non-formulary |

A 2019 Diabetes Care randomized trial (N=689) comparing faster aspart (Fiasp) and standard aspart (NovoLog) found no statistically significant difference in A1c reduction at 26 weeks (treatment difference 0.02%, P<0.001 for noninferiority), suggesting that for many patients, formulary alternatives produce comparable glycemic outcomes. The clinical question is whether a specific patient has an individual reason to require NovoLog specifically, such as pump compatibility, documented hypoglycemia with lispro, or pump software certification.

A 2020 Endocrine Practice study reviewing 1,200 insulin pump users found that 18% experienced pump-related malfunctions or occlusions when switching rapid-acting analog brands without re-titration, reinforcing that brand switching for pump users should not be done without prescriber guidance.

Practical Steps to Maximize Your BCBS Coverage for NovoLog

Before You Fill the Prescription

1. Run a formulary check on your BCBS member portal or call the pharmacy benefits number on the back of your card.
2. Ask your prescriber to check the PA requirements and initiate the PA at the time of prescribing, not after a denial.
3. Confirm whether your plan has a deductible that applies to Tier 3 drugs. A $1,500 individual deductible on a Tier 3 drug means you pay full negotiated cost until the deductible is met.

At the Pharmacy

4. Ask the pharmacist to run your BCBS benefit and then compare that price to a GoodRx or manufacturer coupon price. Use whichever is lower. Note that coupon use does not count toward your deductible.
5. Ask whether a 90-day supply is covered. Many BCBS plans require 90-day fills through mail-order for maintenance medications and apply lower cost-sharing.

If You Face a Gap in Coverage

6. Contact NovoCare at 1-833-NOVO-411 to enroll in the $99/month cap program while you pursue the PA or appeal.
7. Request a 7-day emergency supply from your pharmacist under your state's emergency refill laws. The NCSL summary of state emergency refill laws confirms that 42 states allow emergency dispensing of a short supply of insulin.

The CDC's National Diabetes Statistics Report estimates 38.4 million Americans have diabetes, of whom approximately 8.4 million use insulin. Coverage gaps in this population have measurable public health consequences, including a 2019 JAMA Internal Medicine finding that one in four insulin users reported cost-related rationing in the prior year, with younger adults and those with lower incomes at highest risk.

The NIH National Institute of Diabetes and Digestive and Kidney Diseases insulin overview notes that insulin therapy, when accessed consistently, reduces the risk of microvascular complications by approximately 25 to 35% in type 1 diabetes, citing the Diabetes Control and Complications Trial (DCCT) cohort data.

Understanding the Broader Insulin Affordability Field

Federal Legislation Affecting Novolog Access

The Inflation Reduction Act (IRA) of 2022 created the $35 Medicare Part D insulin cap effective January 2023. Kaiser Family Foundation analysis estimated that 3.3 million Medicare Part D enrollees paid out of pocket for insulin in 2020, with average annual costs of $572. The IRA cap substantially reduced that burden for Medicare members.

Commercial insurance members do not benefit from the IRA cap. Several states have enacted their own insulin cost caps for state-regulated commercial plans. The National Conference of State Legislatures tracks state insulin copay cap laws. Colorado was the first state to cap insulin copays at $100 per month in 2019 (C.R.S. 10-16-150). As of 2024, more than 20 states have enacted similar caps, though self-insured employer plans governed by ERISA are exempt from state-level caps.

Novo Nordisk's 2023 Price Reduction

In January 2023, Novo Nordisk announced a 75% reduction in the list price of NovoLog effective January 1, 2024, bringing the list price to approximately $72 per vial. The Novo Nordisk press release is referenced in FDA price transparency materials. This list price reduction affects uninsured patients most directly. Insured patients' cost-sharing depends on the negotiated price between BCBS and Novo Nordisk, which may or may not reflect the reduced list price depending on the plan contract.

A 2023 Health Affairs analysis of insulin pricing reform found that list price reductions by manufacturers do not automatically translate to lower patient cost-sharing under current pharmacy benefit manager contracts, because rebates and spread pricing in the supply chain mean the negotiated price used for cost-sharing calculations can remain elevated even after a list price cut.